Dr. Katherine Warren
Dr. Warren is an internationally recognized expert in pediatric neuro-oncology. She was appointed Clinical Director of the Stop & Shop Family Pediatric Brain Tumor Program in the Department of Pediatric Oncology in 2019 and was previously Senior Investigator and head of the Neuro-Oncology Section in the Pediatric Oncology branch of the National Cancer Institute where she worked for more than 25 years.
Her major focus is developing new therapeutics to improve the outcome and quality of life for children with CNS tumors. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery. Her clinical trials have led the field in exploring new approaches for the treatment of children with these diseases. Dr. Warren has extensive experience in pharmacology, neuro-imaging, and clinical trial design and incorporates each of these into her research. She has led a number of clinical trials, including single institution, multi-institution, national consortium, and international trials.
Dr. Warren currently serves as the chair of RAPNO (Response Assessment in Pediatric Neuro-Oncology), a member of the NCI Brain Malignancy Steering Committee, NCI Clinical Trials, and Translational Research Advisory Committee Ad hoc Working Group on Glioblastoma, and is a steering committee member for the DIPG Registry. She has served on numerous national and international scientific committees and advisory boards.
Dr. Warren replaces Dr. Mark Kieran, the doctor who treated Zach and had an outstanding impact on DIPG research.